secwatch.observer — SEC 8-K summary
======================================

Issuer:     Lineage Cell Therapeutics, Inc. (LCTX)
CIK:        0000876343
Form:       8-K
Filed at:   2022-10-31T23:59:59+00:00
Accession:  0001493152-22-029913
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Lineage Cell Therapeutics appoints Jill A. Howe as CFO effective Nov 14, 2022
-----------------------------------------------------------------------------

- Ms. Howe will receive an annual salary of $415,000 and a $50,000 sign-on bonus.
- She is eligible for an annual bonus targeted at 40% of salary and granted a stock option for 1,000,000 shares.
- Her prior roles include CFO of DTx Pharma, VP Finance at Gossamer Bio (GOSS), and controller at Amplyx.
- CEO Brian Culley and Sr. Director Alexandra Hernandez will step down from interim CFO and principal accounting officer roles.
- Ms. Howe also serves on boards of Biora Therapeutics (BIOR) and Codagenix Inc.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/876343/000149315222029913/0001493152-22-029913-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/876343/000149315222029913/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-22-029913

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer